Cited by 820Cancer, Lipids, and MetabolismCancer, Hypoxia, and MetabolismLipid metabolism and biosynthesis

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

Open access
Schug, Zachary T., Peck, Barrie, Jones, Dylan T., Zhang, Qifeng, Grosskurth, Shaun, Alam, Israt S., Goodwin, Louise M., Smethurst, Elizabeth +25 more·2015·Cancer Cell

Abstract

A functional genomics study revealed that the activity of acetyl-CoA synthetase 2 (ACSS2) contributes to cancer cell growth under low-oxygen and lipid-depleted conditions. Comparative metabolomics and lipidomics demonstrated that acetate is used as a nutritional source by cancer cells in an ACSS2-dependent manner, and supplied a significant fraction of the carbon within the fatty acid and phospholipid pools. ACSS2 expression is upregulated under metabolically stressed conditions and ACSS2 silencing reduced the growth of tumor xenografts. ACSS2 exhibits copy-number gain in human breast tumors, and ACSS2 expression correlates with disease progression. These results signify a critical role for acetate consumption in the production of lipid biomass within the harsh tumor microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2014.12.002

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some cancers depend on ACSS2 expression, making ACSS2 a potential therapeutic target.

    “Some cancers are nevertheless dependent on expression of acetyl-CoA synthetase 2 (ACSS2), the cytosolic enzyme that allows cells to synthesize acetyl-CoA from acetate, making this represents a potential therapeutic target (Comerford et al., 2014; Schug et al., 2015).”

    From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Schug et al., 2015

  • In cancer cells, citrate becomes labeled following supplementation with isotopically labeled acetate ([13C]acetate), indicating that acetate can undergo oxidation in the TCA cycle in cultured cell lines.

    “In cancer cells, citrate becomes labeled following supplementation of cells with isotopically labeled acetate ([13C]acetate), indicating that acetate can undergo oxidation in the TCA cycle in cultured cell lines (69).”
  • Extracellular acetate is utilized by some cancers as source of acetyl-CoA for biosynthesis.

    “Finally, extracellular acetate has recently been shown to be utilized by some cancers as a source of acetyl-CoA for biosynthesis.”

    From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Schug et al., 2015

  • Brain tumor types including primary glioblastomas and brain metastases assimilate exogenous acetate and incorporate acetate-derived carbons into de novo synthesized fatty acids.

    “Specifically, a variety of tumor types localized to the brain, including primary glioblastomas as well as brain metastases that originated from other tissues, have been shown to assimilate exogenous acetate and incorporate acetate-derived carbons into de novo synthesized fatty acids (Comerford et al., 2014; Mashimo et al., 2014; Schug et al., 2015).”

    From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Schug et al., 2015

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 73 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Schug, Z. T., Peck, B., Jones, D. T., Zhang, Q., Grosskurth, S., Alam, I. S., Goodwin, L. M., Smethurst, E., Mason, S., Blyth, K., McGarry, L., James, D., Shanks, E., Kalna, G., Saunders, R. E., Jiang, M., Howell, M., Lassailly, F., Thin, M. Z., Spencer-Dene, B., Stamp, G., van den Broek, N. J. F., Mackay, G., Bulusu, V., Kamphorst, J. J., Tardito, S., Strachan, D., Harris, A. L., Aboagye, E. O., Critchlow, S. E., Wakelam, M. J. O., Schulze, A., & Gottlieb, E.
Affiliations
  • Cancer Research UK Scotland Institute (GB)
  • Cancer Research UK (GB)
  • John Radcliffe Hospital (GB)
  • Babraham Institute (GB)
  • AstraZeneca (United Kingdom) (GB)
  • Hammersmith Hospital (GB)
  • University of Glasgow (GB)
Corresponding author
Gottlieb, Eyal
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2015-01
Volume
27
Issue
1
Pages
57-71
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2044515618
Cited by
820
References
73
Citations by year
2026: 64 · 2025: 76 · 2024: 96 · 2023: 72 · 2022: 88 · 2021: 75 · 2020: 63 · 2019: 67 · 2018: 68 · 2017: 57 · 2016: 63 · 2015: 28 · 2014: 1 · 2012: 1
FWCI
23.79
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
Funders
  • AstraZeneca
  • Francis Crick Institute (10009, 10008)
  • Cancer Research UK (11359, 18278, 12011, 10337, 16466, 16584, 22311, 18974)
  • National Institute for Health and Care Research (NIHR/CS/009/009, NF-SI-0611-10163, EME/13/122/01)
  • Directorate for Biological Sciences
  • Medical Research Council (MR/J007986/1)
  • Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0415, BBS/E/B/000C0413)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
acetyl-CoA synthetase 2, ACSS2, acetate utilization, cancer cell growth, metabolic stress, hypoxia, lipid depletion, tumor xenografts, fatty acid synthesis, phospholipid synthesis, tumor microenvironment, breast cancer, copy number gain, tumor progression
MeSH terms
Acetate-CoA Ligase, Animals, Hypoxia, Fatty Acids, Humans, Mice, Nude, Neoplasm Transplantation, Neoplasms, Stress, Physiological, Gene Expression Regulation, Neoplastic, Disease Progression, Gene Dosage, Cell Line, Tumor, Cell Proliferation, Mice, MCF-7 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review